- Why High-Flying Aurinia Stock Could Still Be Dirt Cheap
- Baxter International Expects Hit on Q4 Revenue Due to
- Are Analysts Secretly Calling Gilead A Screaming Buy?
- Virtual Humans Work Better Than Current Ways To Identify Post-Traumatic Stress In Soldiers, USC Study Reveals
- Fertility Tests Are A Waste Of Money: Ovarian Reserve Debunked By NIH
- We May Soon Have Our First $1 Million Drug. Who Will Pay For It? And How?
- Boston Scientific, Mayo Clinic File Joint Patent App for Self-Centering TAVR Cath
- Gold ‘Nanoprobes’ Used To Track Blood Flow In Tiny Vessels, University of Birmingham Reveals
- DNA Study Provides Insight Into How To Live Longer, University of Edinburgh Reveals
- Team Reconstructs Nanoscale Virus Features From Correlations Of Scattered X-Rays, Lawrence Berkeley National Laboratory Study
August 13, 2017 / Healthcare
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement of Opicapone for $145M
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America.
Read More
August 13, 2017 / Healthcare
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
Botox maker Allergan Plc agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.
Read More
August 10, 2017 / Healthcare
FDA accepts Merck application for lung cancer combo therapy
Merck & Co on Tuesday said the FDA agreed to a speedy review of its application to combine its immunotherapy...
Read More
August 10, 2017 / Finance
Gundlach: ‘trouble’ for U.S. stocks if 10-year yield hits above 3 percent
There will be "trouble for equity markets" if the yield on the benchmark 10-year U.S. Treasury note moves beyond 3...
Read More
January 9, 2017 / Finance
Wall Street Is Starting to Get Nervous About All the Money Pouring Into U.S. Stocks
After President-elect Donald Trump won the election, markets began a decisive shift in essentially all asset classes. Suddenly, everything from bank stocks to emerging-market...
Read More
January 9, 2017 / Healthcare
France’s Ipsen to buy some Merrimack assets for up to $1 billion
French drugmaker Ipsen SA (IPN.PA) said on Monday it would buy some assets of U.S. peer Merrimack Pharmaceuticals Inc (MACK.O),...
Read More
January 3, 2017 / Healthcare
New drug approvals fall to a six-year low in 2016
Last year turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015's tally of 45.
Read More
January 2, 2017 / Healthcare
U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal
German pharmaceutical company Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition, the U.S. Federal Trade Commission said on Wednesday.
Read More
January 2, 2017 / Finance
The European Union Is Bailing Out Banks Again
Monte dei Paschi di Siena (MPS), the centuries-old bank that is drowning under a growing pile of distressed loans. Since the private sector has now refused to cough up enough capital to close the shortfall identified in this year’s stress tests, it is to be provided with 8.8bn euros of new equity capital, most of it by Italian taxpayers.
Read More
December 22, 2016 / Finance
Goldman, JPMorgan to invest in blockchain startup Axoni: sources
Goldman Sachs Group Inc, JPMorgan Chase & Co and a group of other financial institutions including inter-dealer broker ICAP Plc's venture arm are finalizing an investment in blockchain startup Axoni, people familiar with the deal said this week.
Read More
December 22, 2016 / Healthcare
Senate Report on Sudden Price Hikes in Off-Patent Prescription Drugs
On the heels of headline-grabbing price spikes on prescription drugs, a bipartisan Senate report on Wednesday will call on Congress to take action to prevent huge, unjustified cost increases on decades-old prescription medicines that have no competition.
Read More
December 20, 2016 / Finance
This Is Going to Be Worst Year for IPOs Since the Credit Crisis
Despite the S&P’s 11 percent gain, despite the average 18 percent return for successful IPOs, despite volatility that eased from 2015, the last 12 months have seemed as silent as a graveyard for deals.
Read More
December 20, 2016 / Healthcare
GSK launches big study to test new injection for HIV prevention
GlaxoSmithKline said on Tuesday its HIV unit ViiV Healthcare had started a large study to test an experimental long-acting injection for preventing the virus that causes AIDS.
Read More
December 19, 2016 / Finance
Young Americans Piled Into Some Horrendous ETF Trades Right After the Election
Mimicking President-elect Donald Trump — who has called himself "the king of debt" — risk-loving millennials used exchange-traded funds that...
Read More
December 19, 2016 / Healthcare
Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic
Versant Ventures and Celgene have extended their deal to foster a Toronto-based biotech called Northern Biologics, bringing in a Phase I-ready cancer drug through a merger with a small biotech in Barcelona and pumping in fresh funds to drive its pivot into the clinic.
Read More
December 15, 2016 / Healthcare
Obama Signs Bill to Speed Medical Breakthroughs, Boost NIH Funding
President Barack Obama signed into law the 21st Century Cures Act, a sweeping health package to spur new medical treatments, reform mental health care and provide state grants to curb opioid abuse.
Read More
December 15, 2016 / Healthcare
Lonza to buy U.S. drug capsules maker Capsugel from KKR for $5.5 billion
Lonza Group AG announced its biggest ever acquisition on Thursday with a deal to buy Capsugel, a U.S. maker of capsule products and other drug delivery systems, for $5.5 billion in cash to broaden its product range as a pharmaceuticals industry supplier.
Read More
December 15, 2016 / Finance
Biggest Banks $70 Billion Short in Fed Push to Prevent Bailouts
Wall Street banks are about $70 billion short in building up funds the Federal Reserve says they’ll need to tap following a collapse, down by almost half from the central bank’s earlier estimates.
Read More
December 13, 2016 / Healthcare
Big Pharma’s woeful numbers on drug R&D just got even worse
The analysts at Deloitte continue to calculate a dwindling return for Big Pharma’s R&D dollars.
Read More
December 13, 2016 / Finance
New bank capital rules softened to ease European fears: sources
Global banking regulators have softened proposed new capital rules in a bid to ease European concerns that extra demands would cause banks to crimp their lending, three sources said.
Read More
December 13, 2016 / Finance
Fed gives banks five years to comply with Volcker Rule limits
The Federal Reserve Board laid out on Monday how U.S. banks can apply to take five more years to comply with the Volcker Rule, a reform emerging from the 2007-09 financial crisis that has received some of the harshest criticism from Wall Street.
Read More
December 12, 2016 / Finance
Goldman Says Saudis Wrong to Rule Out U.S. Shale Oil Rebound
Oil may climb to $60 a barrel for the first time in almost a year and a half after Russia and other unaffiliated nations joined an OPEC pledge to reduce production and Saudi Arabia surprised the market by saying it will cut more than previously agreed.
Read More
December 12, 2016 / Finance
Monte Paschi Pushes on With Capital Plan as Rescue Clock Ticks
Banca Monte dei Paschi di Siena SpA is making a last-ditch effort to raise funds as the prospect of a state rescue looms.
Read More
December 9, 2016 / Finance
ECB Expands Stimulus to $2.4 Trillion as Monthly Purchases Slow
The European Central Bank expanded its quantitative-easing program to exceed 2.2 trillion euros ($2.4 trillion) by the end of 2017, buying at a reduced monthly pace with the caveat that it can step up or prolong purchases if needed.
Read More